e-Therapeutics has undergone a major transformation following a strategic review and management changes. The focus remains on exploiting its pioneering work with network-driven drug discovery but the emphasis has shifted onto maximising the potential of its drug discovery platform. The next challenge will be to translate the promising stream of new product leads into meaningful deals and partnerships. The company remains funded into 2019, during which it should generate a number of value inflection points. Our DCFbased valuation yields a value of £53.8m, equivalent to 20.4p a share.
27 Jun 2017
Rebooted drug discovery
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Rebooted drug discovery
e-Therapeutics plc (ETX:LON) | 9.1 -0.1 (-12.2%) | Mkt Cap: 53.2m
- Published:
27 Jun 2017 -
Author:
Mick Cooper PhD -
Pages:
20
e-Therapeutics has undergone a major transformation following a strategic review and management changes. The focus remains on exploiting its pioneering work with network-driven drug discovery but the emphasis has shifted onto maximising the potential of its drug discovery platform. The next challenge will be to translate the promising stream of new product leads into meaningful deals and partnerships. The company remains funded into 2019, during which it should generate a number of value inflection points. Our DCFbased valuation yields a value of £53.8m, equivalent to 20.4p a share.